In a subset of CFS/ME patients, laboratory evaluation reveals objectively confirmed nutritional deficiencies. This finding directly shapes the treatment strategy — identifying which specific deficiency is present is essential before selecting the appropriate intervention.
This protocol applies to CFS/ME patients with biochemically proven nutritional deficiency — a measurable gap confirmed through testing rather than assumed on clinical grounds alone. Current evidence supports performing a biochemical assessment for deficiencies before treatment in order to guide the choice of supplement.
When a biochemically confirmed nutritional gap is identified, management is built around targeted nutritional supplementation tailored to the specific deficiency — with both oral and injectable options available depending on the deficiency profile. The complete regimen, including which agents correspond to which deficiency patterns, is outlined in the full protocol.
Treatment aims to address:
Supplements may benefit CFS/ME patients with specific nutritional deficiencies.
A biochemical test for deficiencies should be performed before treatment in order to guide treatment choices.
There is evidence that supplements may benefit CFS/ME patients; therefore, nutritional supplements should be recommended, at least in CFS/ME patients with a biochemically proven deficiency.
View source ↗